Clinical Trial Update: Paricalcitol for the Treatment of Immunoglobulin A Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating paricalcitol for immunoglobulin A nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: IgA Nephropathy | Phase 3 | Status: WITHDRAWN